{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:59:58Z","timestamp":1794373198402,"version":"4.9.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.drudis.2023.103729","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T11:46:45Z","timestamp":1690804005000},"page":"103729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Advanced pulmonary drug delivery formulations for the treatment of cystic fibrosis"],"prefix":"10.1016","volume":"28","author":[{"given":"Akshay","family":"Parihar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupendra G.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Paliwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maheka","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dignesh","family":"Khunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumedh","family":"Devrao Bahadure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathish","family":"Dyawanapelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2968-2036","authenticated-orcid":false,"given":"Vijayabhaskarreddy","family":"Junnuthula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2023.103729_b0005","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ccm.2007.02.011","article-title":"Cystic fibrosis: a review of epidemiology and pathobiology","volume":"28","author":"Strausbaugh","year":"2007","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.drudis.2023.103729_b0010","unstructured":"Cystic Fibrosis Mutation Database: Statistics. Accessed March 28, 2023, http:\/\/www.genet.sickkids.on.ca\/StatisticsPage.html"},{"key":"10.1016\/j.drudis.2023.103729_b0015","first-page":"101","article-title":"Pathophysiology of cystic fibrosis","volume":"64","author":"Donaldson","year":"2006","journal-title":"Ann Nestle Eng"},{"key":"10.1016\/j.drudis.2023.103729_b0020","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cell.2017.06.041","article-title":"Conformational changes of CFTR upon phosphorylation and ATP binding","volume":"170","author":"Zhang","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2023.103729_b0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/pathophysiology28010011","article-title":"Pathophysiology of lung disease and wound repair in cystic fibrosis","volume":"28","author":"Conese","year":"2021","journal-title":"Pathophysiology"},{"key":"10.1016\/j.drudis.2023.103729_b0030","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/thoraxjnl-2015-207588","article-title":"Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets","volume":"71","author":"Haq","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.drudis.2023.103729_b0035","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/thx.2010.139493","article-title":"Evolution of pulmonary inflammation and nutritional status in infants and young children with cystic fibrosis","volume":"66","author":"Ranganathan","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.drudis.2023.103729_b0040","first-page":"1","article-title":"Inflammatory signalings involved in airway and pulmonary diseases","volume":"2013","author":"Lee","year":"2013","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.drudis.2023.103729_b0045","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1023\/A:1022443209010","article-title":"Modeling of nucleotide binding domains of ABC transporter proteins based on a F1-ATPase\/recA topology: structural model of the nucleotide binding domains of the cystic fibrosis transmembrane conductance regulator (CFTR)","volume":"29","author":"Bianchet","year":"1997","journal-title":"J Bioenerg Biomembr"},{"key":"10.1016\/j.drudis.2023.103729_b0050","doi-asserted-by":"crossref","first-page":"1902443","DOI":"10.1183\/13993003.02443-2019","article-title":"Reimagining cystic fibrosis care: next generation thinking","volume":"55","author":"Rang","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.drudis.2023.103729_b0055","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40272-022-00509-y","article-title":"An update on CFTR modulators as new therapies for cystic fibrosis","volume":"24","author":"King","year":"2022","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.drudis.2023.103729_b0060","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.jcf.2019.12.012","article-title":"New approaches to genetic therapies for cystic fibrosis","volume":"19","author":"Christopher Boyd","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.drudis.2023.103729_b0065","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/MCP.0000000000000827","article-title":"Therapeutic pipeline for individuals with cystic fibrosis with mutations nonresponsive to current cystic fibrosis transmembrane conductance regulator modulators","volume":"27","author":"Fajac","year":"2021","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.drudis.2023.103729_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102248","article-title":"Mucus-targeting therapies of defective mucus clearance for cystic fibrosis: a short review","volume":"65","author":"Figueira","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.drudis.2023.103729_b0075","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.3390\/microorganisms9091874","article-title":"Current and emerging therapies to combat cystic fibrosis lung infections","volume":"9","author":"Manos","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.drudis.2023.103729_b0080","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ppul.25459","article-title":"Cystic fibrosis year in review 2020: Section 2 pulmonary disease, infections, and inflammation","volume":"57","author":"Antos","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.drudis.2023.103729_b0085","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/17460441.2021.1912732","article-title":"Discovery of CFTR modulators for the treatment of cystic fibrosis","volume":"16","author":"Lopes-Pacheco","year":"2021","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.drudis.2023.103729_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.639475","article-title":"Treatment of cystic fibrosis: from gene- to cell-based therapies","volume":"12","author":"Allan","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2023.103729_b0095","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/MCP.0000000000000211","article-title":"The future of CFTR modulating therapies for cystic fibrosis","volume":"21","author":"Davies","year":"2015","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.drudis.2023.103729_b0100","doi-asserted-by":"crossref","first-page":"e00152","DOI":"10.1002\/prp2.152","article-title":"Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR","volume":"3","author":"Farinha","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.drudis.2023.103729_b0105","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomized controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.drudis.2023.103729_b0110","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0022-3476(95)70343-8","article-title":"A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis","volume":"126","author":"Eigen","year":"1995","journal-title":"J Pediatr"},{"key":"10.1016\/j.drudis.2023.103729_b0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1067\/mpd.2003.mpd0332","article-title":"Montelukast pharmacokinetics in cystic fibrosis","volume":"142","author":"Graff","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.drudis.2023.103729_b0120","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S1081-1206(10)61156-8","article-title":"Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis","volume":"95","author":"Stelmach","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.drudis.2023.103729_b0125","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/thorax.56.3.244a","article-title":"Montelukast sodium in cystic fibrosis","volume":"56","author":"Morice","year":"2001","journal-title":"Thorax"},{"key":"10.1016\/j.drudis.2023.103729_b0130","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/17476348.2019.1666715","article-title":"Targeting airway inflammation in cystic fibrosis","volume":"13","author":"McElvaney","year":"2019","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.drudis.2023.103729_b0135","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40204-022-00198-3","article-title":"Therapeutic applications of curcumin nanomedicine formulations in cystic fibrosis","volume":"11","author":"Quispe","year":"2022","journal-title":"Prog Biomater"},{"key":"10.1016\/j.drudis.2023.103729_b0140","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fbioe.2019.00406","article-title":"Nanomedicine approaches for the pulmonary treatment of cystic fibrosis","volume":"7","author":"Velino","year":"2019","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.drudis.2023.103729_b0145","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/17425247.2021.1874343","article-title":"Current and novel therapeutic strategies for the management of cystic fibrosis","volume":"18","author":"Gbian","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.drudis.2023.103729_b0150","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/IJN.S4937","article-title":"Nanomedicine in pulmonary delivery","volume":"4","author":"Mansour","year":"2009","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.drudis.2023.103729_b0155","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.ymthe.2018.05.014","article-title":"Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis","volume":"26","author":"Robinson","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.drudis.2023.103729_b0160","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s12274-020-3180-3","article-title":"Recent applications and strategies in nanotechnology for lung diseases","volume":"14","author":"Zhong","year":"2021","journal-title":"Nano Res"},{"key":"10.1016\/j.drudis.2023.103729_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113191","article-title":"Therapeutic peptides for the treatment of cystic fibrosis: challenges and perspectives","volume":"213","author":"Sala","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2023.103729_b0170","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0169-409X(02)00145-X","article-title":"Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis","volume":"54","author":"Ferrari","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.drudis.2023.103729_b0175","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3390\/jcm8071023","article-title":"Current practices and potential nanotechnology perspectives for pain related to cystic fibrosis","volume":"8","author":"Trandafir","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.drudis.2023.103729_b0180","first-page":"18","article-title":"Synthesis and characterization of multifunctional magnetic nanoparticles for treatment of cystic fibrosis","author":"Jakus","year":"2008","journal-title":"National Nanotechnology Infrastructure Network Published online"},{"key":"10.1016\/j.drudis.2023.103729_b0185","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/magnetochemistry6040072","article-title":"Magnetic nanoparticle-based drug delivery approaches for preventing and treating biofilms in cystic fibrosis","volume":"6","author":"Tan","year":"2020","journal-title":"Magnetochemistry"},{"key":"10.1016\/j.drudis.2023.103729_b0190","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ijpharm.2015.12.028","article-title":"Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis","volume":"498","author":"Moreno-Sastre","year":"2016","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2023.103729_b0195","article-title":"In vitro and in vivo antimicrobial activity of sodium colistimethate and amikacin-loaded nanostructured lipid carriers (NLC)","volume":"29","author":"Vairo","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.drudis.2023.103729_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119696","article-title":"Cefoperazone sodium liposomal formulation to mitigate P. aeruginosa biofilm in cystic fibrosis infection: a QbD approach","volume":"587","author":"Ghodake","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2023.103729_b0205","first-page":"1","article-title":"Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery","volume":"2013","author":"Varshosaz","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.drudis.2023.103729_b0210","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijpharm.2017.05.013","article-title":"Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis","volume":"527","author":"Torge","year":"2017","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2023.103729_b0215","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.2217\/nnm-2020-0344","article-title":"Aerosolized drug-loaded nanoparticles targeting migration inhibitory factors inhibit Pseudomonas aeruginosa induced inflammation and biofilm formation","volume":"15","author":"Doroudian","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.drudis.2023.103729_b0220","first-page":"1752","article-title":"Testing of aerosolized ciprofloxacin nanocarriers on cystic fibrosis airway cells infected with P. aeruginosa biofilms. Drug Deliv","volume":"11","author":"Juntke","year":"2021","journal-title":"Transl Res"},{"key":"10.1016\/j.drudis.2023.103729_b0225","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ejpb.2017.04.032","article-title":"Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections","volume":"117","author":"G\u00fcnday T\u00fcreli","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.drudis.2023.103729_b0230","doi-asserted-by":"crossref","first-page":"e01574","DOI":"10.1128\/AAC.01574-17","article-title":"Antimicrobial activity of ibuprofen against cystic fibrosis-associated gram-negative pathogens","volume":"62","author":"Shah","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2023.103729_b0235","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1477-3155-8-22","article-title":"Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis","volume":"8","author":"Vij","year":"2010","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.drudis.2023.103729_b0240","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41522-022-00317-9","article-title":"Neutralization of ionic interactions by dextran-based single-chain nanoparticles improves tobramycin diffusion into a mature biofilm","volume":"8","author":"Blanco-Cabra","year":"2022","journal-title":"NPJ Biofilms Microbiomes"},{"key":"10.1016\/j.drudis.2023.103729_b0245","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejpb.2020.10.010","article-title":"Spray-dried multidrug particles for pulmonary codelivery of antibiotics with N-acetylcysteine and curcumin-loaded PLGA-nanoparticles","volume":"157","author":"Lababidi","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.drudis.2023.103729_b0250","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijbiomac.2019.04.066","article-title":"Pulmonary delivery of therapeutic proteins based on zwitterionic chitosan-based nanocarriers for treatment on bleomycin-induced pulmonary fibrosis","volume":"133","author":"Zhang","year":"2019","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2023.103729_b0255","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1021\/acsami.7b14992","article-title":"Mucus and cell-penetrating nanoparticles embedded in nano-into-micro formulations for pulmonary delivery of ivacaftor in patients with cystic fibrosis","volume":"10","author":"Porsio","year":"2018","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.drudis.2023.103729_b0260","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejpb.2021.03.012","article-title":"Size shifting of solid lipid nanoparticle system triggered by alkaline phosphatase for site specific mucosal drug delivery","volume":"163","author":"Le-Vinh","year":"2021","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.drudis.2023.103729_b0265","doi-asserted-by":"crossref","first-page":"2100219","DOI":"10.1002\/adtp.202100219","article-title":"Alkaline phosphatase: a reliable endogenous partner for drug delivery and diagnostics","volume":"5","author":"Le-Vinh","year":"2022","journal-title":"Adv Ther (Weinh)"},{"key":"10.1016\/j.drudis.2023.103729_b0270","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.xphs.2022.02.014","article-title":"Preparation and evaluation of charge reversal solid lipid nanoparticles","volume":"111","author":"Federer","year":"2022","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.drudis.2023.103729_b0275","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1021\/acsami.1c14975","article-title":"Hybrid lipid\/polymer nanoparticles to tackle the cystic fibrosis mucus barrier in siRNA delivery to the lungs: does PEGylation make the difference?","volume":"14","author":"Conte","year":"2022","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.drudis.2023.103729_b0280","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1038\/s41598-021-85549-z","article-title":"Assisting PNA transport through cystic fibrosis human airway epithelia with biodegradable hybrid lipid-polymer nanoparticles","volume":"11","author":"Comegna","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2023.103729_b0285","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/09205063.2021.1982159","article-title":"Improvement of anti-biofilm activities via codelivery of curcumin and gentamicin in lipid-polymer hybrid nanoparticle","volume":"33","author":"Sadeghi Mohammadi","year":"2022","journal-title":"J Biomater Sci Polym Ed"},{"key":"10.1016\/j.drudis.2023.103729_b0290","doi-asserted-by":"crossref","first-page":"2100531","DOI":"10.1002\/smll.202100531","article-title":"Tobramycin liquid crystal nanoparticles eradicate cystic fibrosis-related Pseudomonas aeruginosa biofilms","volume":"17","author":"Thorn","year":"2021","journal-title":"Small"},{"key":"10.1016\/j.drudis.2023.103729_b0295","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3390\/biomedicines8090364","article-title":"Capsaicin-loaded chitosan nanocapsules for wtCFTR-mRNA delivery to a cystic fibrosis cell line","volume":"8","author":"Kolonko","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.drudis.2023.103729_b0300","doi-asserted-by":"crossref","first-page":"eabc5911","DOI":"10.1126\/sciadv.abc5911","article-title":"Engineered mutant \u03b1-ENaC subunit MRNA delivered by lipid nanoparticles reduces amiloride currents in cystic fibrosis-based cell and mice models","volume":"6","author":"Mukherjee","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2023.103729_b0305","unstructured":"Sainz Ramos M. Development and characterization of nonviral vectors based on cationic niosomes to address cystic fibrosis disease by gene therapy approach. Doctoral Thesis, University of the Basque Country UPV\/EHU. Published online March 17, 2022. Accessed March 28, 2023, http:\/\/addi.ehu.es\/handle\/10810\/56074"},{"key":"10.1016\/j.drudis.2023.103729_b0310","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.3390\/pharmaceutics14122632","article-title":"Progress on thin film freezing technology for dry powder inhalation formulations","volume":"14","author":"Pardeshi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2023.103729_b0315","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1586\/ers.11.56","article-title":"Tobramycin Inhalation PowderTM: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis","volume":"5","author":"Parkins","year":"2011","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.drudis.2023.103729_b0320","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.2147\/DDDT.S146111","article-title":"The use of amikacin liposome inhalation suspension (Arikayce) in the treatment of refractory nontuberculous mycobacterial lung disease in adults","volume":"14","author":"Khan","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.drudis.2023.103729_b0325","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1513\/AnnalsATS.201811-774OC","article-title":"Oral azithromycin and response to pulmonary exacerbations treated with intravenous tobramycin in children with cystic fibrosis","volume":"16","author":"Klingel","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.drudis.2023.103729_b0330","doi-asserted-by":"crossref","DOI":"10.1177\/1179548419842822","article-title":"Aztreonam lysine inhalation solution in cystic fibrosis","volume":"13","author":"Elson","year":"2019","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"10.1016\/j.drudis.2023.103729_b0335","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/antibiotics10030338","article-title":"Cystic fibrosis: recent insights into inhaled antibiotic treatment and future perspectives","volume":"10","author":"Taccetti","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.drudis.2023.103729_b0340","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jcf.2021.03.002","article-title":"Clinical impact of levofloxacin inhalation solution in cystic fibrosis patients in a real-world setting","volume":"20","author":"Schwarz","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.drudis.2023.103729_b0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2017.05.016","article-title":"Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis","volume":"51","author":"Vardakas","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.drudis.2023.103729_b0350","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3390\/ijms22042155","article-title":"Approaches to targeting bacterial biofilms in cystic fibrosis airways","volume":"22","author":"Martin","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2023.103729_b0355","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3390\/v13091809","article-title":"Phage therapy for multi-drug resistant respiratory tract infections","volume":"13","author":"Iszatt","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2023.103729_b0360","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01991-21","article-title":"Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed","volume":"66","author":"Butler","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2023.103729_b0365","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jcf.2019.05.002","article-title":"Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection","volume":"19","author":"Bentur","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.drudis.2023.103729_b0370","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3390\/jof7110916","article-title":"10th Trends in Medical Mycology held on 8 to 11 October 2021, Aberdeen, Scotland, Organized by the European Confederation of Medical Mycology (ECMM)","volume":"7","author":"Cornely","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.drudis.2023.103729_b0375","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.3390\/ijms22105356","article-title":"Ribosome protection proteins\u2014\u201cNew\u201d players in the global arms race with antibiotic-resistant pathogens","volume":"22","author":"Ero","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2023.103729_b0380","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jac\/dkaa434","article-title":"In vitro assessment of CSA-131 and CSA-131 poloxamer form for the treatment of Stenotrophomonas maltophilia infections in cystic fibrosis","volume":"76","author":"Oyardi","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.drudis.2023.103729_b0385","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1111\/bcp.14326","article-title":"Assessing the impact of cystic fibrosis on the antipyretic response of ibuprofen in children: physiologically-based modeling as a candle in the dark","volume":"86","author":"Cicali","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2023.103729_b0390","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2023.103729_b0395","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00408-020-00353-2","article-title":"Age-dependent progression in lung pathophysiology can be prevented by restoring fatty acid and ceramide imbalance in cystic fibrosis","volume":"198","author":"Youssef","year":"2020","journal-title":"Lung"},{"key":"10.1016\/j.drudis.2023.103729_b0400","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/antibiotics10050486","article-title":"Treatment of pulmonary disease of cystic fibrosis: a comprehensive review","volume":"10","author":"Gir\u00f3n Moreno","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.drudis.2023.103729_b0405","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jcf.2019.08.020","article-title":"Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis","volume":"19","author":"Barth","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.drudis.2023.103729_b0410","article-title":"Timing of dornase alfa inhalation for cystic fibrosis","volume":"2021","author":"Dentice","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.drudis.2023.103729_b0415","article-title":"Timing of hypertonic saline inhalation for cystic fibrosis","volume":"2020","author":"Elkins","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.drudis.2023.103729_b0420","article-title":"Inhaled mannitol for cystic fibrosis","volume":"2020","author":"Nevitt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.drudis.2023.103729_b0425","doi-asserted-by":"crossref","first-page":"00132","DOI":"10.1183\/23120541.00132-2020","article-title":"Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomized, double-blind, placebo-controlled, crossover phase 2b study","volume":"6","author":"van Koningsbruggen-Rietschel","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.drudis.2023.103729_b0430","article-title":"Cystic fibrosis: triple therapy shows promising results","volume":"367","author":"Mahase","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.drudis.2023.103729_b0435","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomized, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2023.103729_b0440","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ppul.23612","article-title":"Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients","volume":"52","author":"Nov\u00e9-Josserand","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.drudis.2023.103729_b0445","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s41030-021-00170-9","article-title":"CFTR modulator therapy and its impact on lung transplantation in cystic fibrosis","volume":"7","author":"Benden","year":"2021","journal-title":"Pulm Ther"},{"key":"10.1016\/j.drudis.2023.103729_b0450","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3390\/ph14090928","article-title":"State of the art on approved cystic fibrosis transmembrane conductance regulator (CFTR) modulators and triple-combination therapy","volume":"14","author":"Meoli","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drudis.2023.103729_bib452","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.3390\/pharmaceutics14091860","article-title":"Polymeric Micelles for Breast Cancer Therapy: Recent Updates, Clinical Translation and Regulatory Considerations","volume":"14","author":"Junnuthula","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2023.103729_bib451","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41467-023-36244-2","article-title":"Future therapies for cystic fibrosis","volume":"14","author":"Allen","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.drudis.2023.103729_bib453","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jcf.2019.06.011","article-title":"Speeding up access to new drugs for CF: considerations for clinical trial design and delivery","volume":"18","author":"Davies","year":"2019","journal-title":"J Cyst Fibros"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623002453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623002453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:06:26Z","timestamp":1761224786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644623002453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":93,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1359644623002453"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103729","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced pulmonary drug delivery formulations for the treatment of cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103729","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103729"}}